Guangshengtang (300436.SZ) released its 2023 annual report. The company achieved operating income of 4.2 during the reporting period...
According to Zhitong Finance App, Guangshengtang (300436.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 423 million yuan, an increase of 9.58% over the previous year; net loss attributable to shareholders of listed companies was 349 million yuan, an increase in year-on-year losses; net losses attributable to shareholders of listed companies were deducted from non-recurring profit and loss of 354 million yuan, an increase in year-on-year losses; and a basic loss per share was 2.1887 yuan/share.
During the reporting period, the company's revenue increased year on year, but net profit was lost. The main reasons were: (1) during the reporting period, it continued to further advance clinical research on innovative drugs and invested a large amount of R&D expenses, with R&D expenses of 132.907 million yuan in 2023; (2) during the reporting period, the company's investment income calculated using the equity method was -6,18415 million yuan, which turned negative and fell sharply year on year, mainly due to the large loss of the associated company Fujian Boao Medical Laboratory Co., Ltd.